Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [1][3]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to contact them regarding their legal rights [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [3]. - The lawsuit claims that the misleading statements about Replimune's business and operations led to investor damages when the true details were revealed [3]. Group 3: Market Reaction - Following the announcement of a Complete Response Letter from the FDA regarding the Biologics License Application for RP1, Replimune's stock fell over 73% during intraday trading on July 22, 2025 [4].

Group 1 - The article promotes a portfolio strategy that generates income without the need for selling assets, aiming to simplify retirement investing [1] - It emphasizes the importance of community and education in investing, suggesting that individuals should not invest alone [2] - The service offers features such as model portfolios, buy/sell alerts, and regular market updates to assist investors [2] Group 2 - The article mentions that the service is supported by contributors who monitor positions and provide exclusive buy and sell alerts to members [4] - It highlights the potential for strong returns through the Income Method, making retirement investing less stressful [1] - The philosophy of the service focuses on creating a vibrant community for investors to engage and learn from each other [2]

Core Insights - Zscaler's stock experienced a 4% decline after reporting strong fiscal Q4 results, but remains up approximately 50% year-to-date [1][2] - The company operates in the zero trust security niche, which is gaining importance in the cybersecurity sector [3] - Zscaler's revenue for the quarter increased by 21% year-over-year to $719.2 million, surpassing management's guidance [5] Financial Performance - Adjusted earnings per share (EPS) rose to $0.89 from $0.72 year-over-year, exceeding the forecast of $0.79 to $0.80 [5] - Operating cash flow was $250.6 million, and free cash flow was $171.9 million, with a cash and short-term investments balance of $3.6 billion [6] - Calculated billings surged by 32% year-over-year to $1.2 billion, while deferred revenue increased by 30% to $2.47 billion, indicating potential revenue growth acceleration [8] Future Guidance - Management forecasts fiscal 2026 revenue between $3.265 billion and $3.284 billion, representing growth of approximately 22% to 23% [9] - For Q1 of fiscal 2026, Zscaler anticipates revenue between $772 million and $774 million, with adjusted EPS between $0.85 and $0.86 [10][11] - The introduction of the Z-Flex payment program has led to a 50% increase in flex billings in fiscal Q4, which could drive further growth [14] Market Position and Strategy - Zscaler is focusing on new growth areas such as AI Security and Zero Trust Everywhere, which contributed to exceeding $1 billion in annual recurring revenue [4] - The company is adapting its strategy by implementing flexible payment options, similar to competitors, to enhance customer engagement [13] - Zscaler's forward price-to-sales multiple is approximately 13, reflecting a fair valuation given its expected revenue growth of around 25% [15]

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether PubMatic and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until October 20, 2025, to request to be appointed as Lead Plaintiff if they purchased PubMatic securities during the Class Period [2]. Group 2: Financial Performance and Market Reaction - On August 11, 2025, PubMatic announced its financial results for Q2 2025, indicating a reduction in ad spend from a top demand side platform (DSP) partner [4]. - The CEO of PubMatic stated that a significant number of clients had shifted to a new platform, causing challenges in inventory valuation [4]. - Following this announcement, PubMatic's stock price fell by $2.23 per share, or 21.1%, closing at $8.34 per share on August 12, 2025 [4].

Group 1 - A class action lawsuit has been filed against Snap, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2][4] - Investors who purchased Snap securities during the Class Period have until October 20, 2025, to request appointment as Lead Plaintiff [2] - Snap reported a deceleration in advertising revenue growth in its Q2 2025 financial results, attributing the slowdown to issues with its ad platform, the timing of Ramadan, and minor changes [4] Group 2 - Following the announcement of the financial results, Snap's stock price fell by $1.61 per share, or 17.15%, closing at $7.78 per share on August 6, 2025 [4]

Group 1 - A class action lawsuit has been filed against LifeMD, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors have until October 27, 2025, to request appointment as Lead Plaintiff if they purchased LifeMD securities during the Class Period [2] - Following the announcement of revised full-year 2025 guidance due to challenges in the Rex MD business, LifeMD's stock price dropped by $5.31, or 44.85%, closing at $6.53 per share [4] Group 2 - LifeMD's CFO stated that the company anticipates strong year-over-year growth in revenue and adjusted EBITDA despite temporary challenges [4] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [5]

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether C3 and certain of its officers and/or direc ...

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Semler and certain of i ...

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Quantum Corporation (“Quantum” or the “Company”) (NASDAQ: QMCO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Quantum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 1 ...

This REIT should have no trouble continuing to increase its dividend in the decades ahead.Realty Income (O 1.60%) has one of the most reliable records of paying dividends in the real estate investment trust (REIT) sector. It has increased its monthly dividend 131 times since its public market listing in 1994, including the past 111 quarters in a row. That's more than three decades of annual dividend increases. With shares currently about 9% below their 52-week high, the dividend yield sits around 5.5%. That ...